

COMPREHENSIVE HEMATOPATHOLOGY REQUISITION

Morphology | Flow Cytometry | Cytogenetics | FISH | Molecular

University of Iowa Diagnostic Laboratories
Department of Pathology
200 Hawkins Drive, 5231 RCP Iowa City, IA 52242

Client Services Toll Free: (866) 844-2522 Client Services Local: (319) 384-7212 Client Services Fax: (319) 384-7213

REQUIRED INFORMATION IN RED CLIENT INFORMATION							
							I
Referring Ins				T _	UIDL Client:		
Requisition C Address:	ompleted By:			Date:			
City:				State:		Zip Code:	
Phone:				Fax:			I
Treating Phys	sician:			Referring Pat	hologist:		
:	FORMATION			Treatming rate	Hologisti		
Last Name:	TORPATION			First Name:			
Gender:	☐ Male		Female	Birth Date:		.	
Address:			remaie	Direit Date.	Phone:		
City:				State:	THORIC.	Zip Code:	
				-		-	
BILLING IN	FORMATION			Th	e UIDL only a	ccepts one bill	ling directive
The below lin the UIDL for t		rtant informati	on to review b	efore selecting a	a billing option	and submitting	a specimen to
https://uidl	.medicine.uic	wa.edu/billi	<u>ng</u>				
Direct Bill							
	ring Instituti	on (Client)					
	nt's Insuranc						
			r referring instituti	on may be billed			
On	date of collect	ion, was vour	patient:				
	Hospital Inpa			ital Outpatient		Non-Hospital	Patient
Patie	nt (Self-Pay)						
		residents without	insurance—Prepayi	ment not required.			
Prepayment				· · ·			
		with non-Iowa	Medicaid or no	insurance			
Non-Iowa Resident with non-Iowa Medicaid or no insurance							
							656 II V
	NFORMATION	l (Plea	se attach sup	porting docun		cluding recent	
Diagosis/ICD	-10 Code(s):				nentation—ine	cluding recent 5.	CBC results) 6.
Diagosis/ICD Clinical Histor	-10 Code(s):	l (Plea	se attach sur 2.	porting docun	4.		6.
Diagosis/ICD- Clinical Histor Phase:	-10 Code(s):	l (Plea	se attach sup	porting docun	4. Acute	5.	6. Blastic
Diagosis/ICD Clinical Histor	-10 Code(s):	l (Plea	se attach sur 2. Chronic	porting docun	Acute New Diagnos	5.	6. Blastic MRD
Diagosis/ICD- Clinical Histor Phase: Diagnosis:	-10 Code(s):	l (Plea	se attach sup 2. Chronic Monitoring	porting docun 3.	Acute New Diagnosi Relapse	5.	6. Blastic
Diagosis/ICD- Clinical Histor Phase: Diagnosis: Treatment:	-10 Code(s): ry:	l (Plea	se attach sup 2. Chronic Monitoring Untreated	porting docun	Acute New Diagnosi Relapse erapy:	5.	Blastic MRD Progression
Diagosis/ICD- Clinical Histor Phase: Diagnosis:	rapy:	l (Plea	se attach sup 2. Chronic Monitoring Untreated Rituxan	porting docun 3.	Acute New Diagnosi Relapse erapy: Gleevec	5.	Blastic MRD Progression Mylotarg
Diagosis/ICD- Clinical Histor Phase: Diagnosis: Treatment:	rapy: Velcade	l (Plea	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo	porting docun 3.	Acute New Diagnosi Relapse erapy: Gleevec Radiation	5.	Blastic MRD Progression Mylotarg Sprycel
Diagosis/ICD-Clinical Histor Phase: Diagnosis: Treatment: Prior Ther	rapy: Velcade GCSF	l (Plea	se attach sup 2. Chronic Monitoring Untreated Rituxan	porting docun 3.	Acute New Diagnosi Relapse erapy: Gleevec	5.	Blastic MRD Progression Mylotarg
Diagosis/ICD-Clinical Histor Phase: Diagnosis: Treatment: Prior Ther	rapy: Velcade GCSF ease specify):	l (Plea	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF	porting docun 3.	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO	5.	Blastic MRD Progression Mylotarg Sprycel Tasigna
Diagosis/ICD-Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple	rapy: Velcade GCSF ease specify): Transplant:	l (Plea	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous	porting docun 3.	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic	5.	Blastic MRD Progression Mylotarg Sprycel
Diagosis/ICD-Clinical Histor Phase: Diagnosis: Treatment: Prior Ther	rapy: Velcade GCSF ease specify): Transplant:	l (Plea	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF	porting docun 3.	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO	5.	Blastic MRD Progression Mylotarg Sprycel Tasigna
Diagosis/ICD Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple Bone Marrow Donor Ge	rapy: Velcade GCSF ease specify): Transplant:	1. Stage:	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous	porting docun 3.	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic Female	5.	Blastic MRD Progression Mylotarg Sprycel Tasigna Sex Mismatch
Diagosis/ICD Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple Bone Marrow Donor Ge	rapy: Velcade GCSF ease specify): Transplant: nder:	1. Stage:	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous	porting docun 3.	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic Female (Recore	5.	Blastic MRD Progression Mylotarg Sprycel Tasigna Sex Mismatch
Diagosis/ICD: Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple Bone Marrow Donor Ge	rapy: Velcade GCSF ease specify): Transplant: nder:	1. Stage:	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous	Current The	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic Female (Recore	5.	Blastic MRD Progression Mylotarg Sprycel Tasigna Sex Mismatch
Diagosis/ICD: Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple Bone Marrow Donor Ge SPECIMEN I Collection Da	rapy: Velcade GCSF ease specify): Transplant: nder: NFORMATIO te:	1. Stage:	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous	Current The	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic Female (Recore	5.	Blastic MRD Progression Mylotarg Sprycel Tasigna Sex Mismatch
Diagosis/ICD-Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple Bone Marrow Donor Ge SPECIMEN I Collection Da Body Site:	rapy: Velcade GCSF ease specify): Transplant: nder: INFORMATIO te: Biopsy:	Stage:	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous Male #:	Collection Tin	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic Female (Record ne (HH:MM):	5.	Blastic MRD Progression Mylotarg Sprycel Tasigna Sex Mismatch s submitted)
Diagosis/ICD-Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple Bone Marrow Donor Ge SPECIMEN I Collection Da Body Site: Bone Marrow	rapy: Velcade GCSF ease specify): Transplant: nder: NFORMATIO te: Biopsy: Aspirate:	Stage: Core	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous Male #: Top #:	Collection Tin	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic Female (Recorne (HH:MM): #: r Top #:	d all specimen	Blastic MRD Progression Mylotarg Sprycel Tasigna Sex Mismatch s submitted)
Diagosis/ICD-Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple Bone Marrow Donor Ge SPECIMEN I Collection Da Body Site: Bone Marrow Bone Marrow	rapy: Velcade GCSF ease specify): Transplant: nder: NFORMATIO te: Biopsy: Aspirate:	N Core Green Green Air Dri	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous Male #: Top #: Top #:	Collection Tin	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic Female (Recorne (HH:MM): #: r Top #:	d all specimen	Blastic MRD Progression Mylotarg Sprycel Tasigna Sex Mismatch s submitted) Top #:
Diagosis/ICD-Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple Bone Marrow Donor Ge SPECIMEN I Collection Da Body Site: Bone Marrow Bone Marrow Peripheral Blo	rapy: Velcade GCSF ease specify): Transplant: nder: NFORMATIO te: Biopsy: Aspirate:	N Core Green Green	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous Male #: Top #: Top #:	Collection Tin	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic Female (Recorne (HH:MM): #: r Top #:	d all specimen	Blastic MRD Progression Mylotarg Sprycel Tasigna Sex Mismatch s submitted) Top #:
Diagosis/ICD-Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple Bone Marrow Donor Ge SPECIMEN I Collection Da Body Site: Bone Marrow Bone Marrow Peripheral Ble Smears:	rapy: Velcade GCSF ease specify): Transplant: nder: NFORMATIO te: Biopsy: Aspirate:	N Core Green Green Air Dri CSF	se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous Male #: Top #: Top #: ed #:	Collection Tin Clot Lavende Lavende Fixed	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic Female (Recorne (HH:MM): #: r Top #: #: #: #: #:	d all specimen Yellow Yellow	Blastic MRD Progression Mylotarg Sprycel Tasigna Sex Mismatch s submitted) Top #: Top #:
Diagosis/ICD Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple Bone Marrow Donor Ge SPECIMEN I Collection Da Body Site: Bone Marrow Bone Marrow Peripheral Blo Smears: Fluid:	rapy: Velcade GCSF ease specify): Transplant: nder: NFORMATIO te: Biopsy: Aspirate:	N Core Green Green Air Dri CSF	Se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous Male #: Top #: Top #: Top #: Ted #: Fumor #:	Collection Tin Clot Lavender Lavender Fixed Pleural	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic Female (Recorne (HH:MM): #: r Top #: #: #: #:	d all specimen Yellow Yellow	Blastic MRD Progression Mylotarg Sprycel Tasigna Sex Mismatch s submitted) Top #: Top #:
Diagosis/ICD Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple Bone Marrow Donor Ge SPECIMEN I Collection Da Body Site: Bone Marrow Bone Marrow Peripheral Blo Smears: Fluid: Fresh Tissue:	rapy: Velcade GCSF ease specify): Transplant: nder: NFORMATIO te: Biopsy: Aspirate:	N Core Green Green Air Dri CSF Solid 1	Se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous Male #: Top #: Top #: Top #: Ted #: Fumor #:	Current The Collection Tin Clot Lavende Lavende Fixed Pleural Lymph N	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic Female (Recore ne (HH:MM): #: r Top #: r Top #: #: #: lode #:	d all speciment Yellow Yellow BAL	Blastic MRD Progression Mylotarg Sprycel Tasigna Sex Mismatch s submitted) Top #: Top #:
Diagosis/ICD Clinical Histor Phase: Diagnosis: Treatment: Prior Ther Other (Ple Bone Marrow Donor Ge SPECIMEN I Collection Da Body Site: Bone Marrow Bone Marrow Peripheral Blo Smears: Fluid: Fresh Tissue: Other*, pleas	rapy: Velcade GCSF ease specify): Transplant: nder: NFORMATIO te: Biopsy: Aspirate: bod:	N Core Green Green Air Dri CSF Solid 1 Block(Se attach sup 2. Chronic Monitoring Untreated Rituxan Chemo GMCSF Autologous Male #: Top #: Top #: Ted #: Immor #: S) #: He review https://uid	Current The Clot Lavender Lavender Fixed Pleural Lymph N Slide(s)	Acute New Diagnosi Relapse erapy: Gleevec Radiation EPO Allogenic Female (Recorne (HH:MM): #: r Top #: #: #: lode #: #: //nucleic-acid-extrace	d all speciment Yellow Yellow BAL	Blastic MRD Progression Mylotarg Sprycel Tasigna Sex Mismatch s submitted) Top #: Top #: #:



COMPREHENSIVE HEMATOPATHOLOGY REQUISITION

Morphology | Flow Cytometry | Cytogenetics | FISH | Molecular

University of Iowa Diagnostic Laboratories
Department of Pathology
200 Hawkins Drive, 5231 RCP Iowa City, IA 52242

Client Services Toll Free: (866) 844-2522

Client Services Local: (319) 384-7212 Client Services Fax: (319) 384-7213

TEST MENU

CONSULT: Morphology, flow cytometry, and chromosome analysis performed.

IHC, FISH, and/or molecular testing possible at the discretion of the pathologist.

For individual orders, please select applicable testing from the following:

IHC								
Tech Only	Tech & Prof	IHC MMR w/ı	reflex to	PCR MSI	Other IHC:			
,		2110111111111			Julio 20101			
ISH								
Tech Only	Tech & Prof	Other ISH:						
FLOW CYTOMETRY								
Evaluate Hematolymp	hoid Malignancy:			В	lood (LAB8255) Bone Ma	arrow (LAB8284	Other (I	AB8254)
Acute Leukemia /	Lymphoblastic Lymp	homa		Paroxysmal Nocturnal Hemoglobinuria (PNH)— Blood Only				
AML MRD				Plasma Cell Neoplasms:				
BALL MRD	BALL MRD			Has the patier	nt received Daratumumab th	nerapy?	Yes	No
Chronic Lymphoc	ytic Leukemia / B-cell	Lymphoma /		Sezary Syr	ndrome			
Mature T-cell Lymphoma				TALL				
Screening for Leukemia / Lymphoma / MDS				T-cell Lym	phoproliferative Diso	rder /		
Mast Cell				Large Grar	nular lymphocytic Leu	ıkemia		
Quantitative—Blood Only: Collected with EDTA tube and processed within 24 hours of collection.								
Autoimmune Lym	phoproliferative Synd	rome L	AB9411	Common Vari	able Immunodeficien	cy (CVID)*		
CD4:CD8 Ratio—	BAL Only	L	AB8254	CVID Pane				LAB9400
Rituximab Panel	-	L	AB9412	CVID WITH	H MEM-B			LAB9405
TBNK Immunophe	enotyping	L	AB9383	CVID + RA	\/RO			LAB9404
1	71 3			CVID + ME	EMB + RA/RO			LAB9406
CD4 Lymphocytes	-Blood Only**	L	AB1280	Fetal Eryth	rocyte Quantitation—	Blood Only*	**	LAB292
* A CBC with automated differential must be ordered and a 3.0 mL lavender top tube sent refrigerated. * Alternatively, send results from CBC with automated differential testing done the day before or the day of shipment.								
** Collected with EDTA tube and processed within 48 hours of collection.					ļ			
l								

*** Collected with EDTA tube and processed within 30 hours of collection.

CYTOGENETICS

Chromosome Analysis LAB8256

FISH	PROCESS & HOLD:		
All FISH probes listed can be ordered individually or as a part of	a predetermined panel LAB8258		
Acute Lymphocytic Leukemia (ALL)	Non-Hodgkin's Lymphoma (NHL)		
B-ALL Pediatric/Adult	Includes: BCL6, CCND1/IgH, IgH/BCL2, MALT1, MYC		
Includes: WHS/CEP4, ABL1/BCR, p16/CEP9, CEP10/PTEN, MLL(KMT2A),	Myeloproliferative Neoplasms (MPN)		
ETV6/RUNX1, CRLF2	Includes: ABL1/BCR, CHIC2, FIP1L1, FGFR1, PDGFRa, PDGFRb		
T-Cell Disorders	Myeloid Disorders (AML/MDS)		
Includes: ALK, D7S522 [7q31], MYC, MLL(KMT2A), p16/CEP9, TCR	Includes: CBFB, D7S522 [-7/7q-], EGR1[-5/5q-], MECOM, MLL(KMT2A), P53, PML/RARA, RNX1/RUNX1T1		
Aneuploidy Screen (AneuVysion)			
Includes: CEPX/Y/18, LSI13/21 [X/Y/13/18/21]	Multiple Myeloma (MM) w/CD138 enrichment		
Chronic Lymphocytic Leukemia (CLL)	Includes: CCND1 XT/IgH, CCND3/IgH, CKS1B/p18 [1q21/1p32], D13S319/13q34 [-13/13q-], FGFR3/IgH, IgH, IgH/MAF, IgH/MAFB, p53/CEP10*, TAS2R1/CEP9/CEP15 [5p15.31/9CEN/15CEN]		
Includes: ATM/p53, CEP12/D13S319/LAMP1 [+12/13q-], MYB/CEP6,			
CCND1/IgH	Reflex probes if IgH BAP is abnormal		
Chronic Myelogenous Leukemia (CML)	Other:		
Includes: ABL1/BCR [9q34/22q11.2]			

MOLECULAR		PROCES	SS & HOLD:
ABL1 TKI Resistance Mutation Detection ^{†, RNA}	LAB8915 LAB8919	JAK2 Reflex for Polycythemia [†]	LAB8540 LAB8542
AML Panel	LAB9075	If JAK2 V617F is negative, reflex to: JAK2	Exon 12, MPL
Includes: ANKRD26, ASXL1, BCOR, BRAF, CBL, CEBPA, D		JAK2 Exon 12 [†]	LAB8052 LAB8054
FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KMT2A (MLL NRAS, PHF6, PPM1D, PTEN, PTPN11, RUNX1, SETBP1, SF.		JAK2 V617F [†]	LAB2472 LAB8031
TET2, TP53, U2AF1, WT1, ZRSR2	321, GNO. 2, GT.162,	Leukemia RNA Fusion Detection ^{†, RNA}	LAB8916
B-Cell IGH Gene Clonality	LAB8283 LAB2471	Myeloproliferative Neoplasia Panel [†]	LAB8429 LAB8430
BCR/ABL t(9;22) ^{+, RNA}	LAB7393 LAB7774	Includes: JAK2 V617F, JAK2 Exon 12, CALR, and MPL	
BRAF/RAS Panel	LAB8092	MPL Codon 515W [†]	LAB8118 LAB8119
CALR [†]	LAB8078 LAB8077	MYD88 Exon 5	LAB8462 LAB8463
CEBPA [†]	LAB7399 LAB7407	Ph-like ALL RNA Gene Fusion ^{†, RNA}	LAB8912
FLT3/NPM1	LAB5732 LAB7865	PML/RARA t(15;17) ^{+, RNA}	LAB9020
JAK2 Reflex Essential Thrombocythemia [†]	LAB8541 LAB8543	T-Cell TRG Gene Clonality	LAB7360 LAB8956
If JAK2 V617F is negative, reflex to: CALR &	& MPL	TP53	LAB8967
† Refrigerate (may not pertain to NA extracts)	•	RNA Due to RNA lability, draw Monday-Thursday only	

COMPREHENSIVE HEMATOPATHOLOGY REQUISITION Morphology | Flow Cytometry | Cytogenetics | FISH | Molecular

University of Iowa Diagnostic Laboratories
Department of Pathology
200 Hawkins Drive, 5231 RCP
Iowa City, IA 52242

Client Services Toll Free: (866) 844-2522 Client Services Local: (319) 384-7212 Client Services Fax: (319) 384-7213

SPECIMEN REQUIREMENTS							
Testing	Specimen Source	Specimen Source	Shipping				
Comprehensive Hematopathology Consultation	(1) Yellow top (ACD Solution) tube, 3.0-5.0 mL (1) Green top (Na Heparin) tube, 3.0-5.0 mL* (1) Lavender top (EDTA) tube, 3.0-5.0 mL Unfixed, air-dried bone marrow aspirate preparations (4-8) Smears AND recent CBC results (1) Core biopsy, >1.0 cm in length in formalin (10 cc vial) (1) Clot, >1.0 cm in length in formalin (10 cc vial) * Include (1) additional green top (Na Heparin) tube for myeloma FISH		Room Temperature				
Flow Cytometry	Bone Marrow <i>OR</i> Peripheral Blood	Lymphoma / Leukemia Panels: (1) Yellow top (ACD Solution) tube, 3.0-5.0 mL Alternatives: Green top (Na Heparin) OR Lavender top (EDTA) tube Quantitative Testing: Must be processed within 24 hours of collection. (1) Lavender top (EDTA) tube, 3.0-5.0 mL Alternative: Pink top (EDTA) tube, 3.0-5.0 mL	Room Temperature				
	Core Biopsy <i>OR</i> Tissue	Fresh RPMI cell media vial	Room Temperature				
Cytogenetics &	Bone Marrow <i>OR</i> Peripheral Blood	(1) Green top (Na Heparin) tube, 3.0-5.0 mL Include (1) additional green top (Na Heparin) tube for myeloma FISH	Room Temperature				
FISH	Tissue	Fresh RPMI cell media vial Archival Formalin-fixed, paraffin embedded	Room Temperature				
Molecular	Bone Marrow <i>OR</i> Peripheral Blood	(1) Lavender top (EDTA) tube, 3.0-5.0 mL	Room Temperature unless test is				
Molecular	Tissue	Fresh RPMI cell media vial Archival Formalin-fixed, paraffin embedded	annotated with "†", then REFRIGERATE				
Nucleic Acid Extracts	Before ordering testing, please review https://uidl.medicine.uiowa.edu/nucleic-acid-extracts for UIDL compliance requirements, and contact the laboratory for additional specimen details (e.g., concentration, elution buffer, transport instructions, etc.) and approval. UIDL may accept NA extract provided it is: 1) an acceptable specimen type; and 2) isolated in a CLIA-certified laboratory or a laboratory meeting equivalent requirements prescribed by the Centers of Medicare and Medicaid Services (CMS). REQUIREMENT: A valid copy of your institution's CLIA certificate, or certificate recognized by CMS.						